ARD-101, a gut-restricted TAS2R agonist, reduces hunger in adults and promotes weight loss in DIO mice with DPP-4 inhibition.
Level 2 - randomized trial
Randomized, placebo-controlled clinical trial in humans combined with preclinical animal models
PubMed 41833222 · doi:10.1016/j.molmet.2026.102340
What was done
Researchers evaluated the gut-restricted bitter taste receptor (TAS2R) agonist denatonium acetate (DA / ARD-101) in both preclinical and clinical studies. Preclinically, mice on a high-fat diet (HFD) or with established diet-induced obesity (DIO) received oral DA (20-80 mg/kg twice daily or 75 mg/kg once daily), sitagliptin-formulated HFD, the combination, or subcutaneous tirzepatide, including an evaluation of weight maintenance after tirzepatide discontinuation. Clinically, randomized, placebo-controlled trials tested ARD-101 in adults with obesity (200 mg twice daily for 28 days; NCT05121441) and in healthy adults (single 800 mg dose) to assess weight, hunger, food cravings, and gut hormones.
What was found
In HFD mice, DA reduced weight gain by up to 43.1%, lowered food intake, and improved glucose and lipid parameters. In DIO mice, DA or sitagliptin alone prevented weight gain, whereas their combination reduced body weight by 18.8%. Following tirzepatide-induced weight loss (-23.7%), switching mice to DA plus sitagliptin limited weight regain similarly to continued tirzepatide. In adults with obesity, ARD-101 reduced weight compared with placebo by 0.8 kg at Day 28 and by 1.3 kg at end-of-study, while also decreasing hunger and food cravings. In healthy participants, a single dose altered gut hormone levels (specific numerical hormone and intake values were not provided in the abstract).
Why it matters
Gut-restricted TAS2R agonism provides a novel oral mechanism for modulating appetite and gut-brain signaling. If validated in longer human trials, it could serve as an oral monotherapy or combination agent with DPP-4 inhibitors to support weight loss and mitigate rebound following incretin discontinuation.
Limits
The abstract does not report the human sample size (n), demographics, or exact numerical changes for gut hormones and metabolic markers. The human trial was short-term (28 days of dosing), showing relatively modest absolute weight loss (1.3 kg difference vs. placebo). Key therapeutic concepts—such as combination therapy with sitagliptin and prevention of weight regain after tirzepatide cessation—were demonstrated only in mouse models.
Cited by
- partial Bitter tastants reduce cravings for sweet foods.